OR WAIT 15 SECS
Clinerion, an eClinical technology services provider located in Basel, Switzerland, and the Alliance for Clinical Research Excellence and Safety (ACRES), a Cambridge, Massachusetts-based non-profit organization operating in the public interest and dedicated to building a global system to enhance quality, safety, integrity and operational effectiveness in biomedical product development and health research, are pleased to announce their partnership for accelerating patient recruitment and promoting risk-based quality management.
By aligning with ACRES integrated data source capabilities housing valuable study and site information, Clinerion's Quality Risk Radar will be able to significantly extend its support of risk-informed decision making during the clinical planning and execution process and thereby maintain and exceed study quality standards. Risk based Monitoring (RBM) becomes a reality when applying Clinerion's consulting and technology services as they enable all clinical research organizations to start projects quickly and rapidly pilot the new RBM approach and enabling technology by taking advantage of FREE and discounted services that Clinerion has pledged to ACRES.
Clinerion will provide to ACRES real-time access to millions of electronic health records (EHRs) coupled with the use of its Patient Recruitment System to find on average 30 times more trial candidates than conventional screening.
"We are delighted to join the ACRES Global Network and are pleased to make our easy-to-implement, industry-hardened solutions in Risk-Based Quality Management and Patient Recruitment available to ACRES. We do this for free or at very attractive conditions and we are convinced that this will translate into significant progress toward the common goals of enhancing quality and operational effectiveness in biomedical product development and health research," said Ulf Claesson, CEO of Clinerion.
ACRES COO, Matthew Whalen, noted, “Our relationship with Clinerion - as a Strategic Ally offering innovative solutions that already exist - demonstrates our ongoing commitment to improve clinical research processes globally and accountably. We are excited to be going forward as allies”.